Dimethyl Fumarate DR Presolicitation
ID: SPE2D2-21-R-0102Type: Presolicitation
Overview

Buyer

DEPT OF DEFENSEDEFENSE LOGISTICS AGENCYDLA TROOP SUPPORTPHILADELPHIA, PA, 19111, USA

PSC

DRUGS AND BIOLOGICALS (6505)
Timeline
    Description

    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.

    Point(s) of Contact
    Files
    Title
    Posted
    The document concerns Solicitation No. SPE2D2-21-R-0102, issued by the Defense Logistics Agency (DLA) for a national contract related to pharmaceutical products, specifically Dimethyl Fumarate in specified dosages. The purpose is to provide a reliable source of these pharmaceutical items for Department of Defense (DoD) customers through the Pharmaceutical Prime Vendor (PPV) program. The contract spans one year, potentially extendable to five years, focusing on ensuring product availability and compliance with government standards. Key points include the contractor's obligations to fulfill orders placed by PPV contractors within stipulated timeframes, the need for compliance with various labeling and packaging requirements, and the establishment of business-to-business agreements with PPV vendors. Delivery must be made within 15 days after receipt of orders, and contractors must notify the DLA of any backorders. Additionally, contractors should be prepared to accept an estimated annual demand and are required to register their products with various drug databases. This Request for Proposal (RFP) emphasizes a structured approach to procuring pharmaceuticals for military healthcare, aiming for efficient distribution, compliance with federal regulations, and maintaining product integrity throughout the supply chain.
    The document serves as an amendment to a solicitation or contract modification, specifically for Golden State Medical Supply Inc., related to contract SPE2D2-23-D-0004. It reflects administrative adjustments, including the exercise of an option for an extension of the contract period from October 28, 2023, to October 27, 2024. The contracting authority emphasizes that all other terms and conditions remain unchanged. Acknowledgment of this amendment is crucial as failure to do so may result in rejection of any submitted offers. The document highlights the importance of compliance with federal procurement processes and ensures that the contractor is informed about the contract continuity and required steps for acknowledgment. Signed by the responsible contracting officer, Jason C. Wray, it underscores the procedural nature of contract management within federal procurement frameworks.
    The document is an amendment to the solicitation/modification of a federal contract numbered SPE2D2-23-D-0004, issued by DLA Troop Support’s Medical Supply Chain. It involves Golden State Medical Supply, Inc., located in Camarillo, California. The purpose of this amendment is to exercise Option 2 of the contract, extending its duration from October 28, 2024, to October 27, 2025. The amendment stipulates that all other terms and conditions of the contract will remain unchanged. Currently, the administering office is identified as SPE2D2, and the modification reflects necessary administrative changes as specified under FAR regulations. The document emphasizes the requirement for the contractor to acknowledge receipt of the amendment and informs them that failure to do so may lead to the rejection of their offer. It is signed by the contracting officer Jason C. Wray, with contact information provided for further inquiries. This modification highlights the continuance of government procurement processes involving medical supplies, ensuring compliance and operational readiness in fulfilling federal obligations.
    This document is an amendment to a federal solicitation, specifically Modification 0001 to Contract ID SPE2D221R0102, issued by DLA Troop Support. The primary purpose of this amendment is to correct key dates related to the solicitation. The solicitation issue date has been revised from July 8, 2021, to August 11, 2021. Additionally, the due date for offers has been updated from August 9, 2021, at 3:00 PM EDT to September 14, 2021, at 3:00 PM EDT. Importantly, all other terms and conditions remain unchanged and in full force. This modification necessitates that contractors acknowledge the receipt of this amendment to ensure compliance with the new deadlines, as failure to do so may result in offer rejection. The document includes guidelines on acknowledging the amendment and clarifies the administrative changes resulting from this modification.
    The document is an amendment to a solicitation related to federal contracts, specifically identified as Amendment 0002 to solicitation SPE2D221R0102. The primary purpose of this amendment is to correct the due date for offer submissions from September 14, 2021, at 9:00 PM EDT to 3:00 PM EDT. It underscores that aside from this modification to the offer due date, all other terms and conditions of the previous document remain intact and operational. Furthermore, it outlines the procedures for contractors to acknowledge the amendment, either through direct communication or by updating their existing offers prior to the new deadline. This amendment serves as a formal notification to potential contractors about the change, ensuring compliance with established procurement processes. Overall, this document reflects standard practices in government Requests for Proposals (RFPs) to ensure clarity and maintain contractual integrity throughout the solicitation process.
    This document serves as an amendment to a federal solicitation regarding Contract ID SPE2D221R0102. The amendment specifies a crucial change: the closing date for offers has been extended from September 14, 2021, to October 14, 2021, at 3:00 PM EST. It emphasizes that all other terms and conditions of the original contract remain unchanged and in full force. The amendment must be acknowledged by contractors, who are required to return a specified number of signed copies to the issuing office. This formal notice is part of the protocol for managing government procurement processes, ensuring that contractors have adequate time to prepare their offers while maintaining compliance with existing guidelines. The amendment is part of standard practices in government contracting, which aim to provide transparency and flexibility in procurement while adhering to regulatory frameworks.
    Lifecycle
    Title
    Type
    Presolicitation
    Similar Opportunities
    Metformin HCL
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is planning to issue a national requirements contract for Metformin HCL ER. The contract will establish a national supply source to provide Metformin HCL ER Tablets in various quantities and bottle sizes. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The items will be purchased by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers through the DLA and VA prime vendor programs. The solicitation will be posted on DLA Bid Board System (DIBBS) and Sam.gov. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is August 2021.
    Metaxalone Tablets
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting proposals for the supply of Metaxalone 800 MG tablets, available in 100-count and 500-count bottles. This procurement aims to establish a requirements contract with estimated annual quantities for a base year and four option years, emphasizing the need for compliance with various federal acquisition regulations and ethical standards. Metaxalone is a critical medication used for muscle relaxation, making this contract vital for supporting military health services. Interested vendors must submit their proposals electronically via the Defense Logistics Agency Internet Bid Board System (DIBBS) between November 7 and December 7, 2025, by 3:00 PM EST. For further inquiries, contact Jeremy Brown at jeremy.brown@dla.mil or Jason Wray at Jason.wray@dla.mil.
    Ondansetron Orally Disintegrating Tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT), specifically 4 MG and 8 MG tablets in various count bottles. This procurement aims to establish a national supply source for these pharmaceutical products, which are critical for treating nausea and vomiting in patients, and will be available for purchase by the Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options, and is expected to be solicited in September 2025, although the DLA reserves the right to issue it earlier or later. Interested parties should direct inquiries to Nancy Fernandez at nancy.fernandez@dla.mil or call 445-737-0713, and are encouraged to set up automated notifications for any changes to the solicitation through the DLA Bid Board System and Sam.Gov.
    Rabeprazole Sodium Delayed Release Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Trazodone - Solicitation
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is soliciting offers for Trazodone HCL tablets in various dosages and bottle counts. This procurement aims to fulfill substantial pharmaceutical supply needs, emphasizing compliance with technical and quality requirements as outlined in the solicitation documents. The solicitation, identified as SPE2D2-26-R-0003, mandates electronic submissions via the Defense Logistics Agency Internet Bid Board System (DIBBS) by December 12, 2025, at 3:00 PM EST, with no alternative submission methods accepted. Interested parties can reach out to Nancy Fernandez at nancy.fernandez@dla.mil or Jason Wray at jason.wray@dla.mil for further inquiries.
    Ibuprofen 400MG/600MG/800MG Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Ibuprofen 400MG/600MG/800MG Tablets. The contract will establish a national supply source to provide the items for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. Interested parties should contact Christopher Newman for any questions/comments. The projected solicitation date is March of 2023.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/ Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency (DHA), is soliciting quotes for a Blanket Purchase Agreement (BPA) and an Additional Discount Program (ADP) for pharmaceutical agents to be included in the DoD Uniform Formulary (UF). This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on oncological agents for myelofibrosis and antihemophilic agents, with evaluations based on clinical and cost-effectiveness. Interested vendors must submit their quotes by January 16, 2026, with a pre-quotation teleconference scheduled for November 20, 2025. For further inquiries, contact Tracy Banks at tracy.e.banks2.civ@health.mil or Stephanie Erpelding at stephanie.j.erpelding.civ@health.mil.
    6505--Carbidopa Levodopa Immediate Release (IR) Tablets
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Carbidopa Levodopa Immediate Release (IR) Tablets, aimed at ensuring a reliable supply for various federal health care entities, including the VA, Department of Defense (DoD), and Bureau of Prisons (BOP). The procurement will involve awarding a single contract for an initial one-year period, with the possibility of four additional one-year option periods, to maintain an uninterrupted supply of these essential medications. The estimated annual requirements detail various dosages and package sizes, with total usage ranging from 2,008 to 118,764 bottles depending on the item. The solicitation is expected to be released around December 18, 2025, with a closing date of January 8, 2026; interested parties should direct inquiries to Ray Roldan at Raymond.Roldan@va.gov or call 708-786-4930.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense (DoD) is issuing a Request for Quotation (RFQ) for pharmaceutical agents to be included in the Uniform Formulary (UF) as part of a Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) for Military Treatment Facilities (MTFs) and TRICARE pharmacies. This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of drugs, which will be evaluated by the Pharmacy and Therapeutics (P&T) Committee. Key drugs under consideration include newly approved agents for lung cancer, antihypertensive agents, oncological agents, diuretics, antilipidemics, and targeted immunomodulatory biologics, with quotes due by January 5, 2026, for a committee meeting scheduled for February 4-5, 2026. Interested manufacturers should contact Tracy Banks or Julia Trang via email for further details and ensure compliance with submission requirements outlined in the RFQ document HT9402-26-Q-9103.